HC Wainwright & Co. Maintains Buy on Silence Therapeutics, Lowers Price Target to $75
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has maintained a Buy rating on Silence Therapeutics (NASDAQ:SLN) but reduced the price target from $80 to $75.
November 17, 2023 | 11:20 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Silence Therapeutics' price target has been lowered from $80 to $75 by HC Wainwright & Co., although the Buy rating is maintained.
The reduction in price target may cause some investors to adjust their valuation models, potentially leading to short-term price fluctuations. However, the maintenance of a Buy rating suggests that the overall outlook for the company remains positive, which could mitigate any negative impact from the price target adjustment.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100